Industry Overview

European dipeptidyl peptidase 4 (DPP-4) inhibitors market was valued at $2.3 billion in 2025 and is projected to reach $3.2 billion by 2035, growing at a CAGR of 3.7% during the forecast period (2026–2035). The European market for DPP-4 inhibitors is experiencing consistent growth, driven by rising demand for effective oral therapies in type 2 diabetes management. Increasing prevalence of diabetes across the region has prompted healthcare providers to expand treatment options. Improved access to medications through hospitals, clinics, and pharmacies has supported wider adoption. Advances in clinical research have enhanced the safety and efficacy profiles of these inhibitors, further encouraging their use. Awareness campaigns and diabetes care programs have contributed to higher patient engagement.

Market Dynamics

Rising Adoption of Sitagliptin and Other Leading DPP-4 Inhibitors

The European DPP-4 inhibitors market is witnessing steady growth driven by increasing clinical adoption of Sitagliptin and other prominent inhibitors. Growing prevalence of type 2 diabetes across Europe has intensified the demand for effective oral therapies. Physicians are favoring these inhibitors due to their proven efficacy, safety, and tolerability in long-term management. Expanded access through hospital networks and retail pharmacies has further supported market penetration. Additionally, patient awareness initiatives and diabetes management programs have encouraged wider use. Collectively, these factors have contributed to the sustained growth of the market in Europe.

Expansion of Generic DPP-4 Inhibitors and Cost-Effective Therapies

The market in Europe is also benefiting from the increasing availability of generic DPP-4 inhibitors, offering cost-effective treatment options. Rising healthcare expenditure and demand for affordable therapies have prompted wider uptake of generics. Regulatory approvals and streamlined distribution channels have facilitated easier access for patients. The introduction of new generic formulations has strengthened competition, leading to broader market reach. Furthermore, insurance coverage and reimbursement policies have enhanced patient accessibility. This trend is expected to drive consistent growth in the European DPP-4 inhibitors segment over the coming years.

Market Segmentation

• Based on the drug type, the market is segmented into sitagliptin and vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, and others.

Sitagliptin Segment to Lead the Market with the Largest Share

Sitagliptin has emerged as a key factor in the growth of the European DPP-4 inhibitors market. Its established clinical efficacy and well-tolerated safety profile have made it a preferred choice among physicians and patients alike. Increasing prescription rates and broader inclusion in treatment guidelines have strengthened its market presence. Expanded distribution through retail and hospital channels has improved patient access. Additionally, educational initiatives and healthcare programs focusing on diabetes management have reinforced its adoption. These elements together are driving steady market momentum for Sitagliptin in Europe.

Linagliptin: A Key Segment in Market Growth

Linagliptin has contributed significantly to the expansion of the European DPP-4 inhibitors market. The drug’s favorable pharmacological profile and convenient dosing regimen have encouraged clinical uptake. Its adoption is supported by growing awareness among healthcare professionals regarding its benefits in type 2 diabetes management. Availability through multiple healthcare channels has improved accessibility for patients. Ongoing research and inclusion in regional treatment protocols have further promoted its use.

Regional Outlook

European dipeptidyl peptidase 4 (DPP-4) inhibitors market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Germany Dominates the Market with Major Share

The DPP-4 inhibitors market in Germany is witnessing steady growth, driven by increasing demand for effective therapies in type 2 diabetes management. Rising prevalence of diabetes and associated complications has prompted greater reliance on oral antidiabetic medications. Physicians are increasingly prescribing DPP-4 inhibitors due to their proven efficacy and favorable safety profile. Improved access through hospitals, specialty clinics, and retail pharmacies has facilitated wider patient adoption. Government initiatives and healthcare programs promoting diabetes awareness have further supported market expansion.

Market Players Outlook

The major companies operating in the European dipeptidyl peptidase 4 (DPP-4) inhibitors market include AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Novartis AG and Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, Azurity Pharmaceuticals, Inc. announced the availability of BRYNOVIN™ (sitagliptin) oral solution, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. BRYNOVIN is not recommended in patients with type 1 diabetes and has not been studied in patients with a history of pancreatitis.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the European dipeptidyl peptidase 4 (DPP-4) inhibitors market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.